- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Nikki Reeves
Insights 29 results
Client Alert
July 28, 2022
A New Day (And A New Acronym) For OTC Drugs
Client Alert
March 28, 2022
AdvaMed Updates Code of Ethics on Interactions with HCPs: What’s the Impact on MedTech?
Article · Source: Chambers and Partners
March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022
Client Alert
January 26, 2022
Spotlight on PFAS and Other Substances in Cosmetics Likely to Grow in 2022
Article · Source: Law360
January 25, 2022
How New Laws Could Tighten FDA Regulation Of Cosmetics
Client Alert
August 17, 2021
Revised PhRMA Code Provides Stricter Controls on HCP Speaker Programs
Client Alert
August 6, 2021
FDA Finalizes “Intended Use” Regulations
Client Alert
June 23, 2021
Pharmaceuticals and Active Pharmaceutical Ingredients - Biden Administration Issues 100-Day Supply Chain Review Report
Article · Source: Chambers and Partners
March 19, 2021
Pharmaceutical Advertising
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Client Alert
September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations
Client Alert
April 17, 2020
Europe Update – Life Sciences Products and COVID-19: From Clinical Trials to Regulatory Flexibility